Apixaban
Eliquis (apixaban) is a small molecule pharmaceutical. Apixaban was first approved as Eliquis on 2011-05-18. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat arthroplasty, stroke, and venous thromboembolism. The pharmaceutical is active against coagulation factor X. Eliquis’s patents are valid until 2031-02-24 (FDA).
Trade Name |
Eliquis |
---|---|
Common Name |
apixaban |
ChEMBL ID |
CHEMBL231779 |
Indication |
arthroplasty, pulmonary embolism, stroke, venous thromboembolism, venous thrombosis |
Drug Class |
Antithrombotic: blood coagulation factor XA inhibitors |
Image (chem structure or protein)
$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-

SQL for web applications

R for statistical modeling

Spotfire & Tableau for visualization

CSV export file format

JSON export file format

XLSX export file format
Continually updated information available as a yearly subscription for individual drug-of-interest.